Fact ✅️: ALL clinical data are relevant to regulatory review beyond any pivotal or larger study. Peer review is also relevant to regulatory review as regulators routinely cite independently peer-reviewed medical journals. Additionally, compassionate use data may be included & considered during a regulatory review.
NWBO is developing a TRIPLE PLATFORM PIPELINE & those platforms will each be included in further research & may become candidates for RA review in a number of nations or regions of the world 🌎